The acceptability of current contraceptive methods to adolescents
Sotnikova, E.I.; Dubnitskaia, L.V.; Perminova, S.G.
Akusherstvo i Ginekologiia 3: 26-30
1993
ISSN/ISBN: 0300-9092 PMID: 8048682 Document Number: 419314
A total of 235 adolescents aged 15-20 years were investigated, of whom 107 (Group I) were using oral contraceptives (OCs) (Trisiston and Anteovin) and 128 (Group II) were using IUDs containing copper: Cu 7-mini, Medusa, and T Cu 200. In addition, 215 women aged 20-35 years were studied in two more groups: 115 were using the OCs Anteovin and Trikvilar (Group III) and 100 were using the IUDs T Cu 200, Cu 7-Standard, and Medusa 1, 2, and 3 (Group IV). The reliability of OCs proved to be complete without even one unplanned pregnancy, while there were 4 such cases in Group II and 3 cases in Group IV. Side effects affected 9.3% among women using OCs in Groups I and III compared to only 7.5% in women at the midpoint of reproductive age. Group I experienced dyspepsia, reduction of work performance, and change in libido, while Group III experienced mammary tension and intermenstrual bleeding. 94.4% of patients in Group I and 94.6% of women in Group III had a menstrual cycle of 28.1 +or- 0.6 days at the beginning of OC use; compared to 27-29 days after the first cycle under OC treatment. Premenstrual syndrome and oligomenorrhea were found in 46.7% of adolescents using OCs and 12.3% of adult OC users at the beginning of treatment; however, by the third month of use menstrual disorders disappeared in all patients, and premenstrual syndrome as well as mammary tension occurred 2-5 days before menstruation in only 2.6% of women in Group III. Among IUD users complications were reported in 9.4% of Group II and 6.3% of Group IV. The frequency of expulsion was around 1.2-2.2 (mean 1.53) per 100 women in the course of 1 year in the adolescent users and 0.67 in Group IV patients. After 4 months of IUD use 73% of adolescents and 80% of women in Group IV experienced bleeding, while IUD removal because of hyperpolymenorrhea had to be done in 1.2% of Group II and 0.7% of Group IV users.